E
The startup develops novel analgesics that target the brain's opioid peptide system to restore the brain reward system's function. This approach aims to treat neurobehavioral symptoms associated with compulsivity, self-injury, and addiction in patients, providing access to effective therapeutic options.
Updated 3 months ago
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops novel analgesics that target the brain's opioid peptide system to restore the brain reward system's function. This approach aims to treat neurobehavioral symptoms associated with compulsivity, self-injury, and addiction in patients, providing access to effective therapeutic options.